UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) June 30, 2020

 

EYENOVIA, INC.

(Exact name of registrant as specified in its charter) 

 

 

 

 

Delaware

(State or other jurisdiction of incorporation)

 
     
001-38365   47-1178401
(Commission File Number)   (IRS Employer Identification No.)

 

295 Madison Avenue, New York, NY 10017

(Address of principal executive offices) (Zip Code)

 

Registrant's telephone number, including area code 917-289-1117

  

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.0001 Par Value EYEN Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

  

 

 

 

 

Item 8.01. Other Events.

 

On June 30, 2020, Eyenovia, Inc. issued a press release announcing that it has resumed patient enrollment for its Phase III CHAPERONE study for the treatment of pediatric progressive myopia. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

  

Item 9.01. Financial Statements and Exhibits.

 

(d)         Exhibits

 

Exhibit No.    Description 
99.1   Press release dated June 30, 2020.

  

 

 

 

 

 

SIGNATURE

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  EYENOVIA, INC.
     
     
Date: June 30, 2020  By:   /s/ John Gandolfo
   

Name: John Gandolfo

Title: Chief Financial Officer

 

 

 

 

 

 

Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more Eyenovia Charts.
Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more Eyenovia Charts.